We are live on
!
Find out more
MoonLake Immunotherapeutics
MLTX
MLTX
147 hedge funds and large institutions have $1.17B invested in MoonLake Immunotherapeutics in 2026 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 49 increasing their positions, 43 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
265% more call options, than puts
Call options by funds: $34M | Put options by funds: $9.32M
90% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 21
58% more capital invested
Capital invested by funds: $743M → $1.17B (+$431M)
14% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 43
13% more funds holding
Funds holding: 130 → 147 (+17)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.5% less ownership
Funds ownership: 88.47% → 87.97% (-0.5%)
Holders
147
Holders Change
+17
Holders Change %
+13.08%
% of All Funds
1.81%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
40
Increased
49
Reduced
43
Closed
21
Calls
$34M
Puts
$9.32M
Net Calls
+$24.7M
Net Calls Change
+$770K
Top Buyers
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$30M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$29.8M |
| 3 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$22.8M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$22.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$15.6M |
Top Sellers
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$62.1M |
| 2 |
Jane Street
New York
|
-$20.3M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$10M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$8.37M |
| 5 |
Morgan Stanley
New York
|
-$7.12M |
